Last updated: May 29, 2026

Examiner: PRIEST, JESSICA MARIE

Tech Center 1600 • Art Units: 1642

This examiner grants 0% of resolved cases

Performance Statistics

—

Allow Rate

-60.0% vs TC avg

Total Applications

—

Interview Lift

Avg Prosecution Days

Based on 0 resolved cases, 2023–2026

§101 Eligibility

§102 Novelty

25.0%

§103 Obviousness

25.0%

§112 Clarity

App #	Title	Status	Assignee
18882177	STABLE FORMULATIONS OF ANTI-CTLA4 ANTIBODIES ALONE AND IN COMBINATION WITH PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF	Non-Final OA	Merck Sharp & Dohme LLC
18563348	IMMUNOMODULATION OF TUMOR MICROENVIRONMENT	Non-Final OA	CLS THERAPEUTICS LIMITED
18467957	ANTI-HUMAN LAIR1 ANTIBODIES	Non-Final OA	TRex Bio, Inc.
17796289	STABLE ANTI-PD-1 ANTIBODY PHARMACEUTICAL FORMULATIONS	Non-Final OA	SAMSUNG BIOEPIS CO., LTD.

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.